

# References

1. National Institute of Health and Care Excellence. Vedolizumab for treating moderately to severely active ulcerative colitis[TA342], 2015
2. National Institute of Health and Care Excellence. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy[TA329], 2015.
3. National Institute of Health and Care Excellence. Ozanimod for treating moderately to severely active ulcerative colitis[TA828], 2022.
4. National Institute of Health and Care Excellence. Tofacitinib for moderately to severely active ulcerative colitis [TA547], 2018.
5. National Institute of Health and Care Excellence. Mirikizumab for treating moderately to severely active ulcerative colitis [ID3973], 2023.
6. National Institute of Health and Care Excellence. Filgotinib for treating moderately to severely active ulcerative colitis, 2022.
7. National Institute of Health and Care Excellence. Ustekinumab for treating moderately to severely active ulcerative colitis, 2020.
8. National Institute of Health and Care Excellence. Risankizumab for previously treated moderately to severely active Crohn's disease, 2023.
9. national Institute of Health and Care Excellence. Ustekinumab for moderately to severely active Crohn's disease after previous treatment, 2017.
10. National Institute of Health and Care Excellence. Upadacitinib for previously treated moderately to severely active Crohn's disease, 2023.
11. National Institute of Health and Care Excellence. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy, 2015.
12. Thorlund K DE, Toor K, Jansen J, Mills EJ. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol 2015;7:29-35.
13. Welty M, Mesana L, Padhiar A, et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin 2020;36(4):595-606. doi: 10.1080/03007995.2020.1716701 [published Online First: 20200129]
14. Varu A, Wilson FR, Dyrda P, et al. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Current Medical Research and Opinion 2019;35(5):733-56. doi: 10.1080/03007995.2019.1580094
15. Dias S, Sutton AJ, Welton NJ, et al. Evidence Synthesis for Decision Making 3: Heterogeneity—Subgroups, Meta-Regression, Bias, and Bias-Adjustment. Medical Decision Making 2013;33(5):618-40. doi: 10.1177/0272989X13485157